Addex reprices officer stock options to $0.032

Q: What did Addex Therapeutics Ltd. (ADXN) disclose about Lenaic Nathanael Teyssedou’s options?

Addex disclosed that Lenaic Nathanael Teyssedou had several existing stock options reported as dispositions and corresponding acquisitions on September 2, 2026, reflecting a repricing of those options to a new exercise price of $0.032 per share, with all other terms unchanged.

Q: Were the Addex Therapeutics (ADXN) options newly granted or repriced?

The options were repriced. Existing stock options originally granted on dates between 2018 and 2024 with higher exercise prices were reported as disposed of to the issuer and replaced by options with an exercise price of $0.032 per share, keeping their other terms the same.

Q: Were the Addex Therapeutics (ADXN) option repricing transactions under a Rule 10b5-1 plan?

The Form 4 indicates that no Rule 10b5-1 trading plan checkbox is marked, and the footnotes do not reference any such plan. The transactions are instead described as exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act.

Addex Therapeutics’ principal accounting officer had multiple option grants repriced to a lower $0.032 exercise price while keeping all other terms unchanged.

Accepted by SEC EDGAR 09/04/2026 - 04:11 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Addex Therapeutics Ltd. (ADXN) reported that its principal accounting officer, Lenaic Nathanael Teyssedou, had multiple existing stock options adjusted on September 2, 2026. Several option awards previously carrying exercise prices including $0.160, $0.053, and $0.062 per share were reported as dispositions to the issuer and corresponding acquisitions of replacement options with an exercise price of $0.032 per share. All other terms of the options, including their original exercise and expiration dates, remain unchanged, and the transactions are described as exempt under Rule 16b-6(d) and Rule 16b-3.

Insider Trade Summary

16 transactions reported

Mixed 16 txns

Insider Teyssedou Lenaic Nathanael

Role PRINCIPAL ACCOUNTING OFFICER

Type	Security	Shares	Price	Value
Disposition	Stock-option (Right to Buy) ^{F2, F1}	37,770	$0.00	$0.00
Grant/Award	Stock-option (Right to Buy) ^{F2, F1}	37,770	$0.00	$0.00
Disposition	Stock-option (Right to Buy) ^{F2, F1}	59,530	$0.00	$0.00
Grant/Award	Stock-option (Right to Buy) ^{F2, F1}	59,530	$0.00	$0.00
Disposition	Stock-option (Right to Buy) ^{F2, F1}	10,000	$0.00	$0.00
Grant/Award	Stock-option (Right to Buy) ^{F2, F1}	10,000	$0.00	$0.00
Disposition	Stock-option (Right to Buy) ^{F2, F1}	30,000	$0.00	$0.00
Grant/Award	Stock-option (Right to Buy) ^{F2, F1}	30,000	$0.00	$0.00
Disposition	Stock-option (Right to Buy) ^{F2, F1}	65,620	$0.00	$0.00
Grant/Award	Stock-option (Right to Buy) ^{F2, F1}	65,620	$0.00	$0.00
Disposition	Stock-option (Right to Buy) ^{F2, F1}	90,529	$0.00	$0.00
Grant/Award	Stock-option (Right to Buy) ^{F2, F1}	90,529	$0.00	$0.00
Disposition	Stock-option (Right to Buy) ^{F2, F1}	208,974	$0.00	$0.00
Grant/Award	Stock-option (Right to Buy) ^{F2, F1}	208,974	$0.00	$0.00
Disposition	Stock-option (Right to Buy) ^{F2, F1}	100,485	$0.00	$0.00
Grant/Award	Stock-option (Right to Buy) ^{F2, F1}	100,485	$0.00	$0.00

Holdings After Transaction: Stock-option (Right to Buy) — 9,043,620 contracts (Direct)

Holdings Before and After: Stock-option (Right to Buy), 9,043,620 to 9,043,620 contracts (Direct)

Footnotes (2)

F1. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.
F2. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.

Key Figures

New exercise price: $0.032 per share Prior exercise price example: $0.160 per share Largest single option block repriced: 208,974 options +3 more

6 metrics

New exercise price $0.032 per share Exercise price of repriced stock options as of September 2, 2026

Prior exercise price example $0.160 per share One of the previous exercise prices for options repriced on September 2, 2026

Largest single option block repriced 208,974 options Block of stock options with prior $0.053 exercise price repriced to $0.032

Another repriced option block 100,485 options Stock-option tranche with prior $0.062 exercise price repriced to $0.032

CHF to USD exchange rate $1.2296 per CHF 1.00 Rate used to convert the repriced exercise price into U.S. dollars

Latest grant’s expiration date January 7, 2034 Expiration date for one repriced option grant originally exercisable from January 8, 2024

Key Terms

Disposition to issuer, Rule 16b-6(d), Rule 16b-3, Stock-option (Right to Buy), +2 more

6 terms

Disposition to issuer financial

"Several option awards were reported as a disposition to issuer and acquisition"

Rule 16b-6(d) regulatory

"transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3"

Rule 16b-3 regulatory

"transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

Stock-option (Right to Buy) financial

"Stock-option (Right to Buy) was the security title for each transaction"

exercise price financial

"the exercise price of the options were repriced to $0.032"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

exchange rate financial

"reflects the conversion from CHF to USD at an exchange rate"

Exchange rate is the price of one currency expressed in another—for example, how many euros you receive for one US dollar. It matters to investors because changes in that price alter the reported profits, costs and value of assets for companies and portfolios that operate or hold money across borders; think of it like switching measurement units, where the same item can look bigger or smaller depending on the unit used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Addex Therapeutics Ltd. (ADXN) disclose about Lenaic Nathanael Teyssedou’s options?

Addex disclosed that Lenaic Nathanael Teyssedou had several existing stock options reported as dispositions and corresponding acquisitions on September 2, 2026, reflecting a repricing of those options to a new exercise price of $0.032 per share, with all other terms unchanged.

Were the Addex Therapeutics (ADXN) options newly granted or repriced?

The options were repriced. Existing stock options originally granted on dates between 2018 and 2024 with higher exercise prices were reported as disposed of to the issuer and replaced by options with an exercise price of $0.032 per share, keeping their other terms the same.

What is the new exercise price of the repriced Addex Therapeutics (ADXN) options?

The repriced stock options for Addex Therapeutics’ principal accounting officer now carry an exercise price of $0.032 per share. Footnotes state this exercise price is reported in U.S. dollars after converting from Swiss francs using a rate of $1.2296 per CHF 1.00 as of September 2, 2026.

What old exercise prices were replaced in the Addex Therapeutics (ADXN) option repricing?

The repricing replaced several previous exercise prices, including $0.160, $0.053, and $0.062 per share, with a new exercise price of $0.032 per share. The underlying options retained their original exercise and expiration dates for each grant.

Were the Addex Therapeutics (ADXN) option repricing transactions under a Rule 10b5-1 plan?

The Form 4 indicates that no Rule 10b5-1 trading plan checkbox is marked, and the footnotes do not reference any such plan. The transactions are instead described as exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act.

How were currency and exchange rate handled for the Addex Therapeutics (ADXN) option repricing?

The exercise price is reported in U.S. dollars and reflects a conversion from Swiss francs. The footnote states the rate used was $1.2296 per CHF 1.00 as of September 2, 2026, which was applied to present the repriced exercise amount in dollars.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Teyssedou Lenaic Nathanael

(Last)

(First)

(Middle)

CHEMIN DES MINES 9

(Street)

GENEVA

CH-1202

(City)

(State)

(Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Addex Therapeutics Ltd. [ ADXN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRINCIPAL ACCOUNTING OFFICER

2a. Foreign Trading Symbol
[ADXN]

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock-option (Right to Buy)	$0.16⁽²⁾	09/02/2026		D⁽¹⁾			37,770	01/08/2018	12/31/2027	Common Stock	37,770	$0	565,138	D
Stock-option (Right to Buy)	$0.032⁽²⁾	09/02/2026		A⁽¹⁾		37,770		01/08/2018	12/31/2027	Common Stock	37,770	$0	602,908	D
Stock-option (Right to Buy)	$0.16⁽²⁾	09/02/2026		D⁽¹⁾			59,530	06/01/2018	05/31/2028	Common Stock	59,530	$0	543,378	D
Stock-option (Right to Buy)	$0.032⁽²⁾	09/02/2026		A⁽¹⁾		59,530		06/01/2018	05/31/2028	Common Stock	59,530	$0	602,908	D
Stock-option (Right to Buy)	$0.16⁽²⁾	09/02/2026		D⁽¹⁾			10,000	04/01/2020	03/31/2030	Common Stock	10,000	$0	592,908	D
Stock-option (Right to Buy)	$0.032⁽²⁾	09/02/2026		A⁽¹⁾		10,000		04/01/2020	03/31/2030	Common Stock	10,000	$0	602,908	D
Stock-option (Right to Buy)	$0.16⁽²⁾	09/02/2026		D⁽¹⁾			30,000	05/17/2021	05/16/2031	Common Stock	30,000	$0	572,908	D
Stock-option (Right to Buy)	$0.032⁽²⁾	09/02/2026		A⁽¹⁾		30,000		05/17/2021	05/16/2031	Common Stock	30,000	$0	602,908	D
Stock-option (Right to Buy)	$0.16⁽²⁾	09/02/2026		D⁽¹⁾			65,620	04/12/2022	04/11/2032	Common Stock	65,620	$0	537,288	D
Stock-option (Right to Buy)	$0.032⁽²⁾	09/02/2026		A⁽¹⁾		65,620		04/12/2022	04/11/2032	Common Stock	65,620	$0	602,908	D
Stock-option (Right to Buy)	$0.16⁽²⁾	09/02/2026		D⁽¹⁾			90,529	10/05/2022	10/04/2032	Common Stock	90,529	$0	512,379	D
Stock-option (Right to Buy)	$0.032⁽²⁾	09/02/2026		A⁽¹⁾		90,529		10/05/2022	10/04/2032	Common Stock	90,529	$0	602,908	D
Stock-option (Right to Buy)	$0.053⁽²⁾	09/02/2026		D⁽¹⁾			208,974	05/12/2023	05/11/2033	Common Stock	208,974	$0	393,934	D
Stock-option (Right to Buy)	$0.032⁽²⁾	09/02/2026		A⁽¹⁾		208,974		05/12/2023	05/11/2033	Common Stock	208,974	$0	602,908	D
Stock-option (Right to Buy)	$0.062⁽²⁾	09/02/2026		D⁽¹⁾			100,485	01/08/2024	01/07/2034	Common Stock	100,485	$0	502,423	D
Stock-option (Right to Buy)	$0.032⁽²⁾	09/02/2026		A⁽¹⁾		100,485		01/08/2024	01/07/2034	Common Stock	100,485	$0	602,908	D

Explanation of Responses:

1. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.

2. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.

	/s/ Lenaic Nathanael Teyssedou	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR